Randomized controlled trials of radiation therapy for cutaneous malignancies: a systematic review.
5 affiliations
- 1Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA.
- 2Medical Library, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 3Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL, USA.
- 4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- 5Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
Abstract
Purpose
In cutaneous oncology, radiotherapy use is largely based on retrospective studies, institutional experience, and expert consensus, with limited high-level evidence to guide practice. We summarize randomized controlled trials in cutaneous radiation oncology and identify gaps in contemporary treatment warranting additional study.Methods and materials
We searched Ovid MEDLINE ALL, Embase.com, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of radiotherapy for cutaneous malignancies: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), melanoma, and Merkel cell carcinoma. Outcomes of interest included recurrence, survival, toxicity and cosmesis. Study inclusion required approval by three authors, with discrepancies resolved by an additional author.Results
Thirteen trials entailing fewer than 2500 patients were identified, with only four studies published in the last decade. Three BCC studies compared radiotherapy with other treatments, while two additional BCC studies and one mixed BCC/SCC study compared dose-fractionation regimens. One SCC study evaluated adjuvant radiotherapy versus chemoradiotherapy. Among five melanoma trials, four evaluated adjuvant radiotherapy, including one for the primary tumor site and three for the regional nodal basin, and one compared definitive radiotherapy with topical imiquimod for unresectable melanoma in situ. One Merkel cell carcinoma trial evaluated lymph node basin radiotherapy.Conclusions
Randomized trials of radiotherapy for cutaneous malignancies are limited, small and heterogeneous, relative to the frequency of these diseases and clinical trials of other therapeutic interventions. Modern randomized trials are needed to bridge these gaps.
Related
- PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials
- Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Single course low-dose radiation therapy in knee osteoarthritis (LoRD-KNeA): a randomized controlled trial
- Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials
- Topical herbal medicine as treatment for chemotherapy-induced peripheral neuropathy: a systematic review of randomized controlled trials
BibTeX
@article{mahase2026randomized,
title = {{Randomized controlled trials of radiation therapy for cutaneous malignancies: a systematic review.}},
author = {Sean S Mahase and Joseph Miccio and Marina Chilov and Laila A Gharzai and Christopher A Barker and Nicholas G Zaorsky},
journal = {Clinical and translational radiation oncology},
year = {2026},
month = oct,
doi = {10.1016/j.ctro.2026.101317},
url = {https://europepmc.org/article/MED/42921462},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Randomized controlled trials of radiation therapy for cutaneous malignancies: a systematic review.
AU - Sean S Mahase
AU - Joseph Miccio
AU - Marina Chilov
AU - Laila A Gharzai
AU - Christopher A Barker
AU - Nicholas G Zaorsky
PY - 2026
DA - 2026/10/14
JO - Clinical and translational radiation oncology
DO - 10.1016/j.ctro.2026.101317
UR - https://europepmc.org/article/MED/42921462
AB - Purpose In cutaneous oncology, radiotherapy use is largely based on retrospective studies, institutional experience, and expert consensus, with limited high-level evidence to guide practice. We summarize randomized controlled trials in cutaneous radiation oncology and identify gaps in contemporary treatment warranting additional study.Methods and materials We searched Ovid MEDLINE ALL, Embase.com, and the Cochrane Central Register of Controlled Trials for randomized controlled trials of radiotherapy for cutaneous malignancies: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), melanoma, and Merkel cell carcinoma. Outcomes of interest included recurrence, survival, toxicity and cosmesis. Study inclusion required approval by three authors, with discrepancies resolved by an additional author.Results Thirteen trials entailing fewer than 2500 patients were identified, with only four studies published in the last decade. Three BCC studies compared radiotherapy with other treatments, while two additional BCC studies and one mixed BCC/SCC study compared dose-fractionation regimens. One SCC study evaluated adjuvant radiotherapy versus chemoradiotherapy. Among five melanoma trials, four evaluated adjuvant radiotherapy, including one for the primary tumor site and three for the regional nodal basin, and one compared definitive radiotherapy with topical imiquimod for unresectable melanoma in situ. One Merkel cell carcinoma trial evaluated lymph node basin radiotherapy.Conclusions Randomized trials of radiotherapy for cutaneous malignancies are limited, small and heterogeneous, relative to the frequency of these diseases and clinical trials of other therapeutic interventions. Modern randomized trials are needed to bridge these gaps.
SN - 2405-6308
ER -